# Sirigen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sirigen

- Industry: Biotechnology
- Headquarters: Ringwood, UK
- Website: www.sirigen.com
- Total disclosed funding: $1.7M
- Latest round: Series B (Apr 24, 2008)
- Investors on record: 3

## About

Sirigen Ltd. focuses on advanced diagnostics and multiplexed biomarker detection technology, enhancing genomic and proteomic analysis for clinical laboratories and research institutions to improve patient outcomes.Sirigen Ltd., based in Ringwood, UK, specializes in advanced diagnostic solutions. In August 2012, Sirigen was acquired by Becton, Dickinson and Company for an undisclosed sum. The company has successfully engaged in 9 deals since its inception. Sirigen's latest funding round, amounting to GBP 2.000 mn, was led by prominent investors such as IQ Capital, NESTA Investments, Oxford Capital Partners, Seraphim Space Manager, and YFM Equity Partners. The total amount raised by the company stands at GBP 2.000 mn, indicating a focused investment strategy on its technology development.Sirigen specializes in advanced diagnostics and analysis through its innovative product offerings, primarily focusing on multiplexed biomarker detection technology. The core products aim to enhance efficiency and accuracy in genomic and proteomic analysis, serving platforms that cater to clinical laboratories and research institutions. The products are designed to provide insights into various health conditions, facilitating personalized medicine approaches and improving patient outcomes. This technology was notably released to the market to address the growing need for precise diagnostic tools in oncology and infectious diseases. Sirigen's client base includes academic research facilities, healthcare providers, and diagnostic laboratories across Europe, North America, and select markets in Asia, where the demand for sophisticated diagnostic solutions continues to rise.In the most recent fiscal year of 2011, Sirigen reported revenue of GBP 770,238.1 with an EBITDA of GBP 14,002.5. The revenue generation model for Sirigen involves strategic partnerships with healthcare institutions and direct sales to clinical laboratories, which utilize the company's proprietary diagnostic technologies. Transactions typically occur through B2B agreements, with clients purchasing diagnostic kits and technology solutions tailored to their specific needs. The pricing structure is influenced by the complexity and range of services offered, with flagship products commanding premium pricing due to their advanced capabilities and proven efficacy. Revenue streams are further supported by ongoing collaborations and support services provided to clients, ensuring that they maximize the utility of Sirigen's product offerings. These financial arrangements are structured to foster long-term client relationships while delivering cutting-edge diagnostic solutions.Following the acquisition by Becton, Dickinson and Company, Sirigen is expected to enhance its product offerings and explore new market opportunities. The funding received will facilitate ongoing research and development, focusing on the design and launch of new diagnostic products targeted for release in the near future. Expansion into new markets, particularly in Asia and North America, is anticipated to occur within the next few years as the company aims to increase its footprint in the diagnostics sector. The recent funding will support these initiatives, driving innovation and enabling Sirigen to meet the growing demand for advanced diagnostic solutions.

## Funding rounds

- Series B, Apr 24, 2008, $0.5M — Oxford Capital Partners, Seraphim Space Manager
- Series A, Mar 31, 2006, $1.2M — Persistence Partners

## Investors

- Persistence Partners (https://capitalatlas.ai/funds/persistence-partners) — Series A
- Oxford Capital Partners (https://capitalatlas.ai/funds/oxford-capital-partners) — Series B
- Seraphim Space Manager (https://capitalatlas.ai/funds/seraphim-space-manager) — Series B